The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
Participated in Study mRNA-3927-P101.
Completed the EOT/ET visit in Study mRNA-3927-P101 and enroll in this study such that the first dose in this study is planned to be within 14±3 days of the last dose of mRNA-3927 in the mRNA-3927-P101 study.
Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.
Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.
History of liver and/or kidney transplant.
Single group
mRNA-3927
Biological/VaccinemRNA-3927 dispersion for IV infusion
Number of Participants with Adverse Events (AEs), Serious AEs (SAEs), and AEs Leading to Discontinuation
Annualized Frequency of Investigator-reported Metabolic Decompensation Events (MDEs)
Annualized Frequency of Investigator-reported MDE-related Hospitalizations
Annualized Frequency of Investigator-reported PA-related Hospitalizations
Annualized Frequency of Investigator-reported PA-related Urgent Healthcare Encounters
Click on the lead sponsor to view all of their trials.
